B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Key Account Manager - Hematology

Full-Time
€110.4k - €138k
Mid
Bachelor's
Remote in Netherlands
Remote
Sales & Account ManagementAccount Management

About the job

Requirements
  • A life sciences degree or equivalent professional experience.
  • Multiple years of qualified field-based commercial experience in specialty care, preferably in hemato-oncology, with a strong track record of frequent face-to-face, remote, and digital engagement with key healthcare professionals and hospital stakeholders.
  • Demonstrated experience managing complex hospital accounts in the Netherlands.
  • Proven ability to gain, maintain, and expand access to healthcare professionals and relevant hospital stakeholders in access-restricted environments.
  • Demonstrated ability to design and execute personalized omnichannel engagement plans, including face-to-face, remote, virtual, and approved digital channels.
  • Proven ability to manage accounts in a structured, data-driven manner.
  • Demonstrated experience leading account-level projects or initiatives from insight generation through planning, execution, stakeholder follow-up, and impact measurement.
  • Experience using customer relationship management systems and Sales Force Excellence principles to plan, document, track, and improve customer engagement and account performance.
  • Ability to translate account insights into concrete actions, customer engagement plans, and measurable business outcomes.
  • Fluency in Dutch at native or near-native level and professional English.
  • A valid Dutch driver's license.
Responsibilities
  • Own end-to-end relationships with a defined portfolio of priority hospital accounts, with clear accountability for regular, proactive, documented engagement with senior clinical, scientific, pharmacy, nursing, and other relevant hospital stakeholders.
  • Develop, maintain, and continuously refine comprehensive account profiles and plans covering organizational structure, formulary status, buying group affiliations, key decision-makers, care pathways, competitive positioning, and patient flow dynamics.
  • Identify key unmet needs at account level—clinical, operational, and educational—and translate them into co-created, account-specific initiatives that deliver measurable mutual value beyond product promotion.
  • Map and actively manage the full account stakeholder ecosystem, including hematologists, specialist nurses, and hospital pharmacists.
  • Establish and maintain stakeholder influence maps, identifying decision-makers versus influencers and tailoring engagement accordingly.
  • Open, maintain, and broaden access with priority accounts, including when direct healthcare professional access is constrained, through compliant, creative, and value-adding engagement approaches.
  • Position BeOne as a long-term partner through value-based collaboration, insight-driven engagement, and customer-centric problem-solving in the hospital.
  • Build, execute, and continuously update high-quality account plans for all priority accounts, grounded in patient potential, competitive dynamics, formulary status, institutional priorities, stakeholder mapping, omnichannel engagement opportunities, and unmet needs.
  • Monitor and interpret prescription trends, treatment sequencing, switching behavior, and formulary developments, translating insights into actionable commercial strategies.
  • Quantify patient potential by line of therapy and relevant clinical sub-segments to ensure plans are based on realistic patient flow assumptions.
  • Maintain a good understanding of account structures, patient flows, key stakeholders, and decision-making processes to identify opportunities.
  • Provide relevant account insights to support business planning, forecasting discussions, and decision-making when needed.
  • Ensure accurate, timely, and complete customer relationship management documentation of customer interactions, account insights, next steps, stakeholder preferences, channel use, and agreed follow-up actions, using the system as a planning, execution, and performance-management tool.
  • Lead regular cross-functional account reviews, aligning Commercial and Medical priorities into a single, integrated account plan.
  • Drive sustainable demand through credible, compliant communication of clinical and patient-relevant value propositions.
  • Support onboarding of new prescribers, ensuring they have the confidence, practical resources, and scientific understanding to initiate and manage patients appropriately.
  • Facilitate evidence-based patient profiling discussions, supporting appropriate use across relevant hematologic indications.
  • Identify opportunities to support reassessment of treatment approaches aligned with evolving clinical evidence, patient needs, and local account priorities.
  • Execute indication-specific growth strategies aligned to national priorities and local account realities.
  • Translate national brand strategy into concrete account-level actions, including defined target customers, call priorities, engagement frequency, patient profile activation opportunities, and measurable account outcomes.
  • Design, execute, and continuously optimize omnichannel and digital engagement plans tailored to stakeholder access preferences, digital maturity, customer journey stage, and role-specific communication needs.
  • Orchestrate face-to-face visits, remote interactions, virtual meetings and symposia, approved email or digital content, customer relationship management-enabled follow-up, and other approved non-personal promotion channels into one coherent customer journey.
  • Treat every channel interaction as part of a single coordinated customer journey, ensuring consistency of message and continuity of relationship.
  • Maintain customer relationship management logging discipline across all engagement channels and activate recruitment of email consents in a compliant way.
  • Use approved digital tools and compliant professional platforms, where permitted by company policy and local regulations, to identify engagement opportunities, strengthen customer relationships, and extend the impact of account plans; this may include approved and appropriate use of professional platforms such as LinkedIn.
  • Monitor engagement channel effectiveness and adapt the customer journey based on customer response, access constraints, customer relationship management insights, and account performance.
  • Identify, develop, lead, and implement account-level value-added initiatives that address clinical, operational, or educational needs, with clear objectives, stakeholder alignment, measurable outcomes, and documented impact, in line with compliance standards.
  • Apply structured project management discipline to value-added services initiatives by defining objectives, timelines, success metrics, stakeholder responsibilities, and review checkpoints from initiation through completion and impact measurement.
  • Ensure all value-added services projects are tracked in customer relationship management systems and reviewed as part of quarterly account plan cycles.
  • Collaborate closely with Medical Affairs on peer-to-peer initiatives and scientific exchange activities, ensuring clear role clarity and compliance.
  • For priority accounts, identify and progress relevant value-added initiatives where there is a clear customer need, mutual value, compliance alignment, agreed milestones, and an assigned BeOne owner.
  • Act as the central point of account intelligence for cross-functional teams.
  • Coordinate with medical science liaisons to deploy scientific expertise at high-impact moments along the customer journey.
  • Translate new scientific data, guideline updates, and competitive developments into account-specific actions.
  • Lead structured account discussions with cross-functional colleagues, ensuring clear roles, actions, owners, timelines, and follow-up.
  • Bring actionable customer and account insights back to the organization to inform forecasting, campaign planning, access priorities, and resource allocation.
  • Operate in line with Sales Force Excellence principles, with clear ownership of in-field healthcare professional visit coverage, frequency, quality, and key performance indicator performance.
  • Ensure timely, accurate, and complete documentation of customer interactions and activities in customer relationship management systems.
  • Take accountability for results, proactively identifying performance gaps and implementing corrective actions.
  • Use approved tools and materials consistently and compliantly.
  • Spend the majority of working time in customer-facing and account-facing activities, with approximately 70% field and customer engagement time, subject to business needs, travel requirements, and manager guidance.
  • Deliver against agreed activity, quality, coverage, frequency, customer relationship management, and account progression key performance indicators, as defined by the Sales Director and the company’s Sales Force Effectiveness Framework.
  • Conduct all activities in full compliance with Dutch and European Union regulations, the CGR code, and internal company policies.
  • Ensure timely and accurate reporting of adverse events, medical inquiries, and product complaints.
  • Act as a role model for ethical, patient-centric behavior within the field team.
Desired Qualifications
  • Direct experience in hematology or oncology.
  • An established network with Dutch hematology stakeholders, hospital pharmacists, or relevant institutional decision-makers.
  • Strong experience developing and leading field commercial projects and initiatives.
  • Experience working in a cross-functional, global environment.
  • Experience contributing to launch, growth, or turnaround situations in specialty care.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.